MedTrace Logo

Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)

NCT04650152 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2021-12-15

No results posted yet for this study

Summary

This study is a prospective observational program within the frames of which Tricor (fenofibrate) is prescribed to patients with hypertriglyceridemia within a routine procedure as a part of the combination therapy with statins.

Conditions

  • Hypertriglyceridemia
  • Metabolic Syndrome

Interventions

DRUG

Tricor (fenofibrate), 145 mg, film-coated tablet

Observational study without intervention. Fenofibrate is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.

Sponsors & Collaborators

Principal Investigators

  • Irina Solnyshkina · Abbott

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-27
Primary Completion
2021-11-12
Completion
2021-11-12

Countries

  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04650152 on ClinicalTrials.gov